vs
MEDIFAST INC（MED）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
MEDIFAST INC的季度营收约是RIGEL PHARMACEUTICALS INC的1.1倍（$75.1M vs $69.8M），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs -36.9%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs -34.4%）
迈德福斯特是一家总部位于美国马里兰州巴尔的摩的营养减重企业，该公司研发、分销并销售减重及健康相关产品，销售渠道涵盖官方网站、多层次营销、电话销售以及品牌加盟减重诊所。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
MED vs RIGL — 直观对比
营收规模更大
MED
是对方的1.1倍
$69.8M
营收增速更快
RIGL
高出58.1%
-36.9%
两年增速更快
RIGL
近两年复合增速
-34.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.1M | $69.8M |
| 净利润 | — | $268.1M |
| 毛利率 | 69.4% | 91.5% |
| 营业利润率 | -10.4% | 33.2% |
| 净利率 | — | 384.0% |
| 营收同比 | -36.9% | 21.2% |
| 净利润同比 | — | 1769.2% |
| 每股收益（稀释后） | $-1.64 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MEDRIGL
| Q4 25 | $75.1M | $69.8M | ||
| Q3 25 | $89.4M | $69.5M | ||
| Q2 25 | $105.6M | $101.7M | ||
| Q1 25 | $115.7M | $53.3M | ||
| Q4 24 | $119.0M | $57.6M | ||
| Q3 24 | $140.2M | $55.3M | ||
| Q2 24 | $168.6M | $36.8M | ||
| Q1 24 | $174.7M | $29.5M |
净利润MEDRIGL
| Q4 25 | — | $268.1M | ||
| Q3 25 | $-2.3M | $27.9M | ||
| Q2 25 | $2.5M | $59.6M | ||
| Q1 25 | $-772.0K | $11.4M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | $1.1M | $12.4M | ||
| Q2 24 | $-8.2M | $-1.0M | ||
| Q1 24 | $8.3M | $-8.2M |
毛利率MEDRIGL
| Q4 25 | 69.4% | 91.5% | ||
| Q3 25 | 69.5% | 93.2% | ||
| Q2 25 | 72.6% | 95.6% | ||
| Q1 25 | 72.8% | 91.7% | ||
| Q4 24 | 74.1% | 89.9% | ||
| Q3 24 | 75.4% | 85.5% | ||
| Q2 24 | 73.2% | 92.4% | ||
| Q1 24 | 72.8% | 93.1% |
营业利润率MEDRIGL
| Q4 25 | -10.4% | 33.2% | ||
| Q3 25 | -4.6% | 40.9% | ||
| Q2 25 | -1.0% | 60.1% | ||
| Q1 25 | -1.1% | 23.9% | ||
| Q4 24 | 0.6% | 28.9% | ||
| Q3 24 | 1.5% | 25.4% | ||
| Q2 24 | -4.7% | 1.2% | ||
| Q1 24 | 4.5% | -23.6% |
净利率MEDRIGL
| Q4 25 | — | 384.0% | ||
| Q3 25 | -2.5% | 40.2% | ||
| Q2 25 | 2.3% | 58.6% | ||
| Q1 25 | -0.7% | 21.5% | ||
| Q4 24 | — | 24.9% | ||
| Q3 24 | 0.8% | 22.5% | ||
| Q2 24 | -4.8% | -2.8% | ||
| Q1 24 | 4.8% | -27.9% |
每股收益（稀释后）MEDRIGL
| Q4 25 | $-1.64 | $14.11 | ||
| Q3 25 | $-0.21 | $1.46 | ||
| Q2 25 | $0.22 | $3.28 | ||
| Q1 25 | $-0.07 | $0.63 | ||
| Q4 24 | $0.08 | $0.82 | ||
| Q3 24 | $0.10 | $0.70 | ||
| Q2 24 | $-0.75 | $-0.06 | ||
| Q1 24 | $0.76 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.3M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $198.9M | $391.5M |
| 总资产 | $248.0M | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资MEDRIGL
| Q4 25 | $167.3M | $155.0M | ||
| Q3 25 | $173.5M | $137.1M | ||
| Q2 25 | $162.7M | $108.4M | ||
| Q1 25 | $164.6M | $77.1M | ||
| Q4 24 | $162.3M | $77.3M | ||
| Q3 24 | $170.0M | $61.1M | ||
| Q2 24 | $163.5M | $49.1M | ||
| Q1 24 | $156.4M | $49.5M |
总债务MEDRIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益MEDRIGL
| Q4 25 | $198.9M | $391.5M | ||
| Q3 25 | $214.7M | $117.6M | ||
| Q2 25 | $216.0M | $81.9M | ||
| Q1 25 | $211.0M | $18.6M | ||
| Q4 24 | $210.1M | $3.3M | ||
| Q3 24 | $207.3M | $-14.6M | ||
| Q2 24 | $205.3M | $-29.9M | ||
| Q1 24 | $211.0M | $-31.7M |
总资产MEDRIGL
| Q4 25 | $248.0M | $513.6M | ||
| Q3 25 | $268.2M | $242.5M | ||
| Q2 25 | $269.3M | $206.7M | ||
| Q1 25 | $280.0M | $176.0M | ||
| Q4 24 | $284.2M | $164.0M | ||
| Q3 24 | $291.2M | $139.4M | ||
| Q2 24 | $293.5M | $128.4M | ||
| Q1 24 | $302.8M | $126.5M |
负债/权益比MEDRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.3M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $-6.6M | — |
| 自由现金流率自由现金流/营收 | -8.8% | — |
| 资本支出强度资本支出/营收 | 1.8% | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | $1.2M | — |
8季度趋势，按日历期对齐
经营现金流MEDRIGL
| Q4 25 | $-5.3M | $22.0M | ||
| Q3 25 | $12.1M | $24.0M | ||
| Q2 25 | $-3.4M | $30.5M | ||
| Q1 25 | $3.4M | $-893.0K | ||
| Q4 24 | $-4.9M | $14.5M | ||
| Q3 24 | $9.1M | $21.7M | ||
| Q2 24 | $13.1M | $302.0K | ||
| Q1 24 | $7.3M | $-5.0M |
自由现金流MEDRIGL
| Q4 25 | $-6.6M | — | ||
| Q3 25 | $10.8M | — | ||
| Q2 25 | $-4.8M | — | ||
| Q1 25 | $1.9M | — | ||
| Q4 24 | $-7.2M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $11.1M | — | ||
| Q1 24 | $5.4M | — |
自由现金流率MEDRIGL
| Q4 25 | -8.8% | — | ||
| Q3 25 | 12.0% | — | ||
| Q2 25 | -4.5% | — | ||
| Q1 25 | 1.6% | — | ||
| Q4 24 | -6.1% | — | ||
| Q3 24 | 5.5% | — | ||
| Q2 24 | 6.6% | — | ||
| Q1 24 | 3.1% | — |
资本支出强度MEDRIGL
| Q4 25 | 1.8% | — | ||
| Q3 25 | 1.5% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 1.1% | — | ||
| Q1 24 | 1.1% | — |
现金转化率MEDRIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | -1.36× | 0.51× | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | 8.04× | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
